Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Relapsed/Refractory NK/T Cell Lymphoma and PTCL
NCT03701022Phase 2Unknown
- Sponsor
- Peking University
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in Natural killer T-cell lymphoma (NKTL), peripheral T-cell lymphoma (PTCL), sponsored by Peking University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Natural killer T-cell lymphoma (NKTL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03701022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701022.